
ARDT Stock Forecast & Price Target
ARDT Analyst Ratings
Bulls say
Ardent Health Inc. exhibited strong financial performance with an EBITDA of $143 million, reflecting a significant year-over-year growth of 46% and an improved margin of 9.1%, up 240 basis points. The company reported a 2.9% increase in admissions, aligning with the high end of its annual guidance, indicating robust operational growth. Additionally, ongoing favorable trends in the hospital sector, along with opportunities for advancing its outpatient strategy, suggest that Ardent is well-positioned to enhance its earnings potential moving forward.
Bears say
The negative outlook on Ardent Health Inc. is primarily driven by a disappointing EBITDA performance, which, despite a year-over-year increase, fell 2% short of estimates due to an inflated third-quarter figure influenced by a pull forward of $15M-$20M from the subsequent quarter. Furthermore, the company is experiencing a significant revenue adjustment of $43M linked to its transition to the Kodiak revenue cycle management platform, casting doubt on accounts receivable collectability and leading to reduced growth expectations. As a result, financial projections for 2025 and 2026 have been substantially lowered, indicating a potential transition to minimal or negative EBITDA growth, reflected in a 9% cut to 2025 EBITDA guidance.
This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.
ARDT Analyst Forecast & Price Prediction
Start investing in ARDT
Order type
Buy in
Order amount
Est. shares
0 shares